RxDoctor Payments Data

Brooke Bear, DO

Internal Medicine · Winterville, NCNPI 1437353612

Payments from drug & device makers

$2,137in general payments, 2019–2025

Across 128 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$425
  • AstraZeneca$268
  • Amgen$242
  • AbbVie$210
  • Pfizer$178
  • Astellas Pharma US Inc$117
  • plus $696 from 21 others

What the payments were for

  • Food & beverage$2,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,137 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$542,536
Medicare patients
919
Services billed
15,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$191,752
OzempicSemaglutide124$127,538
JardianceEmpagliflozin108$124,691
Humira(Cf) PenAdalimumab13$87,744
FarxigaDapagliflozin Propanediol76$76,971
RybelsusSemaglutide55$73,710
JanuviaSitagliptin Phosphate50$63,966
XareltoRivaroxaban47$55,428
MounjaroTirzepatide43$46,329
Repatha SureclickEvolocumab52$34,601
MyrbetriqMirabegron36$30,904
TrulicityDulaglutide33$30,068
ArexvyRsvpref3 Antigen/As01e/Pf73$23,082
NexletolBempedoic Acid16$16,166
Repatha PushtronexEvolocumab21$15,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$425$201,248179 claims
PfizerEliquis, Premarin$178$196,259180 claims
Boehringer IngelheimJardiance$31$124,691108 claims
AstraZenecaFarxiga, Symbicort$268$88,194109 claims
Lilly USA, LLCMounjaro, Trulicity$27$76,39776 claims
GSKArexvy, Shingrix$45$37,808139 claims
Astellas Pharma US IncMyrbetriq$117$30,90436 claims
AbbVieLinzess$210$9,77915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Winterville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →